Stimplate (romiplostim biosimilar) / Generium - LARVOL DELTA

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - P3 | N=160 | Completed | Sponsor: AO GENERIUM | Enrolling by invitation ➔ Completed

Trial completion • Hematological Disorders • Thrombocytopenic Purpura

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (clinicaltrials.gov) - P3 | N=160 | Completed | Sponsor: AO GENERIUM | Recruiting ➔ Completed

Trial completion • Hematological Disorders • Thrombocytopenic Purpura

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - P3 | N=160 | Enrolling by invitation | Sponsor: AO GENERIUM | Trial primary completion date: Nov 2023 ➔ Apr 2024

Trial primary completion date • Hematological Disorders • Thrombocytopenic Purpura

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients (clinicaltrials.gov) - P3 | N=160 | Enrolling by invitation | Sponsor: AO GENERIUM | Trial completion date: Aug 2023 ➔ Jan 2024 | Trial primary completion date: Jun 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Hematological Disorders • Thrombocytopenic Purpura

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP (clinicaltrials.gov) - P3 | N=160 | Recruiting | Sponsor: AO GENERIUM | Trial completion date: Feb 2023 ➔ Jan 2024 | Trial primary completion date: Jan 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Hematological Disorders • Thrombocytopenic Purpura